A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects

A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects

Background: Phosphodiesterase 10A (PDE10A) is expressed almost exclusively in the striatum and its inhibition is suggested to offer potential treatment in disorders associated with basal ganglia. We evaluated the selectivity, cytotoxicity, genotoxicity, pharmacokinetics and potential adverse effects...

Full description

Bibliographic Details
Main Authors: Mikolaj Matloka, Sylwia Janowska, Piotr Pankiewicz, Sofiya Kokhanovska, Tomasz Kos, Małgorzata Hołuj, Izabela Rutkowska-Wlodarczyk, Krzysztof Abramski, Monika Janicka, Piotr Jakubowski, Maciej Świątkiewicz, Marlena Welniak-Kaminska, Joanna Hucz-Kalitowska, Paulina Dera, Lukasz Bojarski, Paweł Grieb, Piotr Popik, Maciej Wieczorek, Jerzy Pieczykolan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Pharmacology
Subjects:
CPL500036
PDE10A inhibitor
lead characterization
drug development
safety evaluation
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.999685/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.999685/full

Similar Items